Displaying 1 - 3 of 3
| Active Ingredient | CYPROTERONE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Advanced prostatic carcinoma. |
| Caution |
Impotence, inhibition of spermatogenesis, headache, gynecomastia, galactorrhea, weight gain, lipid abnormalities, gastrointestinal disturbances and anemia. Several cases of hep ato More ... |
| Dose Range | Palliative treatment: 200- 300 mg daily in 2 or 3 divided doses after meals. S uppression of disease flare: 100 mg twice daily used alone for 5 to 7 day s, then with a gonadorelin analogue for 3 to 4 weeks. |
| Drug Interactions | |
| Pregnancy | Use of cyproterone during pregnancy might carry a risk of feminisation of a male More ... |
| Breast Feeding |
| Active Ingredient | CYPROTERONE | ETHINYL ESTRADIOL |
| Therapeutic Class | CONTRACEPTIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OESTRADIOL | CYPROTERONE |
| Therapeutic Class | COMBINED PREPARATIONS FOR MENOPAUSAL SYMPTOMS |
| Indications | Symptoms due to oestrogenic deficiency ,and for the prophylaxis of postmenopausal osteoporosis in women at risk of developing fractures. |
| Caution |
Headache, dizziness, nausea, changes in bleeding patterns. Do not chew tablets, swallow whole. |
| Dose Range | 1 tablet daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |